Stereotaxis Receives FDA Clearance For Synchrony System

April 06, 2026 — 08:46 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Stereotaxis (STXS) said it has received FDA 510(k) clearance for the Synchrony system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony's 55 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab. It is made available with SynX, a cloud-based HIPAA and GDPR-compliant app that allows for secure remote connectivity, collaboration, recording, and monitoring of the cath lab.

Stereotaxis reiterated its guidance of over $3 million in revenue in the current year from Synchrony systems placed independent of robotic systems.

In pre-market trading on NYSE American, Stereotaxis shares are up 5.8 percent to $2.0.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Stereotaxis Receives FDA Clearance For Synchrony System

Tags

Latest Articles